In this preclinical study, we provide robust evidence that the combination of baricitinib, a JAK1/2 inhibitor, and lonafarnib, a farnesyltransferase inhibitor, offers significant therapeutic benefits in delaying the progression of HGPS. The gene discussed is JAK1; the disease is Hutchinson-Gilford progeria syndrome.